SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Discovery of Innovative Therapeutics: Today’s Realities and Tomorrow’s Vision. 2. Pharma’s Challenges and Their Commitment to Innovation
16 references·1 citing·39 second hop
Discovery of Innovative Therapeutics: Today’s Realities and Tomorrow’s Vision. 2. Pharma’s Challenges and Their Commitment to Innovation (2014)Discovery of Innovative Therapeutics: Tod…Pharmaceutical Research and Development: What Do We Get for All that Money? (2012)Pharmaceutical Research and D…Mergers and innovation in the pharmaceutical industry (2012)Mergers and innovation in the…Diagnosing the decline in pharmaceutical R&D efficiency (2012)Diagnosing the decline in pha…US academic drug discovery (2011)US academic drug discoveryThe impact of mergers on pharmaceutical R&D (2011)The impact of mergers on phar…Small (molecule) thinking in academia (2011)Small (molecule) thinking in …Believe it or not: how much can we rely on published data on potential drug targets? (2011)Believe it or not: how much c…The patent cliff steepens (2010)The patent cliff steepensLessons from 60 years of pharmaceutical innovation (2009)Lessons from 60 years of phar…Balancing Innovation and Access: Patent Challenges Tip the Scales (2009)Balancing Innovation and Acce…Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R & D Productivity (2008)Mergers and Alliances in Phar…Mergers and acquisitions in the pharmaceutical and biotech industries (2007)Mergers and acquisitions in t…Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks (2006)Inter-firm R&D partnering in …Motivations for strategic alliances in the pharmaceutical/biotech industry: Some new findings (2004)Motivations for strategic all…Can the pharmaceutical industry reduce attrition rates? (2004)Can the pharmaceutical indust…Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985). (1988)Pharmaceutical innovation by …Mitigating risk in academic preclinical drug discovery (2015)Mitigating risk in academic p…The price of innovation: new estimates of drug development costs (2003)Clinical development success rates for investigational drugs (2014)Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology (1996)The black swan: the impact of the highly improbable (2007)Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework (2014)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)How to improve R&D productivity: the pharmaceutical industry's grand challenge (2010)Investigating the factors that diminish the barriers to university–industry collaboration (2010)Open for collaboration: an academic platform for drug discovery and development at SciLifeLab (2016)Opportunities and Challenges for Drug Development: Public–Private Partnerships, Adaptive Designs and Big Data (2016)Pharmaceutical Industry, Academia, Regulatory Authorities and End User Collaboration in Successful Drug Discovery and Development (2021)Why Most Published Research Findings Are False (2005)What errors do peer reviewers detect, and does training improve their ability to detect them? (2008)Power failure: why small sample size undermines the reliability of neuroscience (2013)Estimating the reproducibility of psychological science (2015)Why Most Published Research Findings Are False (2019)Two new Later Stone Age sites from the Final Pleistocene in the Falémé Valley, eastern Senegal (2024)Capitalism, Socialism and Democracy (1997)The Theory of Economic Development (2003)Influence of government R&D support and inter-firm collaborations on innovation in Korean biotechnology SMEs (2011)Managing open innovation projects with science-based and market-based partners (2014)Changing R&D models in research-based pharmaceutical companies (2016)Social and Private Rates of Return from Industrial Innovations* (1977)Vertical integration and innovation (2016)When Risks Cannot Be Seen: Regulating Uncertainty in Emerging Technologies (2016)How mergers affect innovation: Theory and evidence (2018)Agency Costs of Free Cash Flow, Corporate Finance, and Takeovers (1986)The Modern Industrial Revolution, Exit, and the Failure of Internal Control Systems (1993)Agency costs of free cash flow, corporate finance, and takeovers (1996)The Persistent Effect of Geographic Distance in Acquisition Target Selection (2013)The role of geographic distance in completing related acquisitions: Evidence from U.S . chemical manufacturers (2015)Are Ideas Getting Harder to Find? (2020)Generating Theory by Abduction (2021)Market spiral pricing of cancer drugs (2013)Are new models needed to optimize the utilization of new medicines to sustain healthcare systems? (2014)R&D Costs of New Medicines: A Landscape Analysis (2021)Defining “Innovativeness” in Drug Development: A Systematic Review (2013)Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications (2017)Importance of tacit knowledge in incremental innovation (2017)
this work references cited by second hop

References

  • 2004Can the pharmaceutical industry reduce attrition rates?4,230 cited
  • 2012Diagnosing the decline in pharmaceutical R&D efficiency2,039 cited
  • 2011Believe it or not: how much can we rely on published data on potential drug targets?1,885 cited
  • 2009Lessons from 60 years of pharmaceutical innovation1,238 cited
  • 1988Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).471 cited
  • 2006Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks311 cited
  • 2012Pharmaceutical Research and Development: What Do We Get for All that Money?256 cited
  • 2007Mergers and acquisitions in the pharmaceutical and biotech industries236 cited
  • 2012Mergers and innovation in the pharmaceutical industry114 cited
  • 2011The impact of mergers on pharmaceutical R&D109 cited
  • 2011US academic drug discovery101 cited
  • 2009Balancing Innovation and Access: Patent Challenges Tip the Scales96 cited
  • 2004Motivations for strategic alliances in the pharmaceutical/biotech industry: Some new findings76 cited
  • 2010The patent cliff steepens68 cited
  • 2008Mergers and Alliances in Pharmaceuticals: Effects on Innovation and R & D Productivity

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work

34 cited
  • 2011Small (molecule) thinking in academia29 cited
  • Cited by

    • 2015Mitigating risk in academic preclinical drug discovery192 cited